Journal
JOURNAL OF CANCER
Volume 11, Issue 22, Pages 6633-6641Publisher
IVYSPRING INT PUBL
DOI: 10.7150/jca.47025
Keywords
Nitroxoline; Bladder cancer; EMT; immunotherapy preclinical model
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology of Japan [17K11138]
- Science and Technology Planning Project of the Guangdong Province [2016A020215109]
- China Scholarship Council
- Grants-in-Aid for Scientific Research [17K11138] Funding Source: KAKEN
Ask authors/readers for more resources
Nitroxoline is considered to be an effective treatment for the urinary tract infections. Recently, it has been found to be effective against several cancers. However, few studies have examined the anti-tumor activity of nitroxoline in bladder cancer. The purpose of the study was to reveal the possible mechanisms how nitroxoline inhibited bladder cancer progression. In vitro assay, we demonstrated that nitroxoline inhibited bladder cancer cell growth and migration in a concentration-related manner. Western blot analysis demonstrated that nitroxoline downregulated the expressions of epithelial mesenchymal transition (EMT)-related proteins. Furthermore, treatment with nitroxoline in the C3H/He mice bladder cancer subcutaneous model resulted in significant inhibition of tumor growth. Moreover, the percentage of myeloid-derived suppressor cells (MDSC) in peripheral blood cells significantly decreased after treatment of nitroxoline. Taken together, our results suggested that nitroxoline may be used as a potential drug for bladder cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available